These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20029156)

  • 1. Resolution of macular edema in Coats' disease with intravitreal bevacizumab.
    Entezari M; Ramezani A; Safavizadeh L; Bassirnia N
    Indian J Ophthalmol; 2010; 58(1):80-2. PubMed ID: 20029156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolution of severe macular edema in adult coats' disease with intravitreal triamcinolone and bevacizumab injection.
    Jun JH; Kim YC; Kim KS
    Korean J Ophthalmol; 2008 Sep; 22(3):190-3. PubMed ID: 18784449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease.
    Cakir M; Cekiç O; Yilmaz OF
    J AAPOS; 2008 Jun; 12(3):309-11. PubMed ID: 18589387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis.
    Moon SJ; Berger AS; Tolentino MJ; Misch DM
    Ophthalmic Surg Lasers Imaging; 2007; 38(2):164-6. PubMed ID: 17396701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats' disease in children.
    Kaul S; Uparkar M; Mody K; Walinjkar J; Kothari M; Natarajan S
    Indian J Ophthalmol; 2010; 58(1):76-8. PubMed ID: 20029154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Coats disease with bevacizumab in 2 patients.
    Venkatesh P; Mandal S; Garg S
    Can J Ophthalmol; 2008 Apr; 43(2):245-6. PubMed ID: 18347637
    [No Abstract]   [Full Text] [Related]  

  • 7. Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab.
    He YG; Wang H; Zhao B; Lee J; Bahl D; McCluskey J
    Graefes Arch Clin Exp Ophthalmol; 2010 Oct; 248(10):1519-21. PubMed ID: 20379736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coats' disease: treatment with intravitreal bevacizumab and laser photocoagulation.
    Stergiou PK; Symeonidis C; Dimitrakos SA
    Acta Ophthalmol; 2009 Sep; 87(6):687-8. PubMed ID: 18976310
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravitreal bevacizumab therapy for idiopathic macular telangiectasia.
    Matsumoto Y; Yuzawa M
    Jpn J Ophthalmol; 2010 Jul; 54(4):320-4. PubMed ID: 20700800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined intravitreal bevacizumab and argon laser treatment for Coats' disease.
    Cackett P; Wong D; Cheung CM
    Acta Ophthalmol; 2010 Mar; 88(2):e48-9. PubMed ID: 19500078
    [No Abstract]   [Full Text] [Related]  

  • 12. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.
    Charbel Issa P; Holz FG; Scholl HP
    Ophthalmology; 2007 Sep; 114(9):1736-42. PubMed ID: 17822979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment for Coats' disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases.
    Kodama A; Sugioka K; Kusaka S; Matsumoto C; Shimomura Y
    BMC Ophthalmol; 2014 Mar; 14():36. PubMed ID: 24666524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia.
    Rishi P; Rishi E; Shroff D
    Indian J Ophthalmol; 2009; 57(3):241-2. PubMed ID: 19384026
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of intravitreal bevacizumab injection as the initial treatment for Coats' disease.
    Zheng XX; Jiang YR
    Graefes Arch Clin Exp Ophthalmol; 2014 Jan; 252(1):35-42. PubMed ID: 23873253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab in the treatment of idiopathic macular telangiectasia.
    Gamulescu MA; Walter A; Sachs H; Helbig H
    Graefes Arch Clin Exp Ophthalmol; 2008 Aug; 246(8):1189-93. PubMed ID: 18386039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful use of intravitreal bevacizumab and pascal laser photocoagulation in the management of adult Coats' disease.
    Raoof N; Quhill F
    Middle East Afr J Ophthalmol; 2013; 20(3):256-8. PubMed ID: 24014992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Juxtafoveal telangiectasias.
    Querques G; Delle Noci N
    Ophthalmology; 2008 Sep; 115(9):1636; author reply 1636. PubMed ID: 18762079
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of intravitreal triamcinolone and bevacizumab in Coats' disease with central macular edema.
    Böhm MR; Uhlig CE
    Graefes Arch Clin Exp Ophthalmol; 2011 Jul; 249(7):1099-101. PubMed ID: 21318335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.
    Iturralde D; Spaide RF; Meyerle CB; Klancnik JM; Yannuzzi LA; Fisher YL; Sorenson J; Slakter JS; Freund KB; Cooney M; Fine HF
    Retina; 2006 Mar; 26(3):279-84. PubMed ID: 16508427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.